CXCL13
Use
CXCL13 is a chemokine originally discovered to interact with the CXCR5/BLR1 receptor expressed on B cells in Burkitt’s Lymphoma. It functions in normal B cell germinal center formation in spleen and lymphatic tissues and plays a role in regulating lymphocytic infiltration in the tumor microenvironment and lymphoproliferative neoplasms. It's an important differentiator for nodal T follicular helper lymphoma of the angioimmunoblastic type.
Special Instructions
Not provided.
Limitations
Biopharma availability is limited to use in clinical trials or research purposes only. Turnaround times are subject to change based on biopharma protocol requirements, with final times specified in the study contract. Specimens fixed in any other fixatives than 10% NBF or B plus will be rejected.
Methodology
Immunoassay (IHC)
Biomarkers
CXCL13
Protein
Result Turnaround Time
2 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (Fixed (Non-FFPE))
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Fixative should be at a 20:1 fixative to tissue ratio, 10% neutral buffered formalin (NBF) for 6-72 hours (48-72 hours PREFERRED).
Storage Instructions
15°C to 25°C. Use a refrigerated gel pack for shipment.
Causes for Rejection
Specimens must be fixed in 10% NBF or B plus. All other fixatives will be rejected.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | ≤ 72 Hours |